RD人恶性胚胎横纹肌瘤细胞(STR鉴定正确)

价 格:¥1800

期 货:现货(冻存管发2支)

保藏中心:BTCC

资源编号:BTCC-1226

产地:中国

套 餐:

T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

详细资料说明书下载质检报告(COA)

Cell line nameRD
SynonymsR D; RD-2; RD 2; 130T; 130-T; 130 T; TE-32; TE 32; TE32; TE 32.T; Te 32.T
AccessionBTCC-1226
Secondary accessionBTCC-1226
Resource Identification InitiativeTo cite this cell line use: RD (BTCC-1226)
CommentsPart of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Population: Caucasian.
Doubling time: 23 hours (PubMed=20922763).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Cell surface proteome.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Exosome proteome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Pelvis, muscle; UBERON=UBERON_0001325.
Sequence variations
HLA typingSource: PubMed=77569
Class I
HLA-AA*01
HLA-BB*08,w15

Source: PubMed=26589293
Class I
HLA-AA*01:01,01:01
HLA-BB*37:01,37:01
HLA-CC*06:02,06:02
Class II
HLA-DQDQA1*04:01,04:01

DQB1*06:04,06:04
HLA-DRDRB1*10:01,13:05
Genome ancestrySource: PubMed=30894373

Origin% genome


African3.96
Native American0
East Asian, North4.77
East Asian, South0
South Asian0
European, North53.65
European, South37.61
DiseaseEmbryonal rhabdomyosarcoma (NCIt: C8971)
Embryonal rhabdomyosarcoma (ORDO: Orphanet_99757)
Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
HierarchyChildren:



CVCL_LM95 (3AB-OS)CVCL_0350 (IN157)CVCL_C1YP (RD rho-0)
CVCL_XD25 (RD-Luc)CVCL_A5IA (RD-SCARB2)CVCL_DP30 (RD.TG6)
CVCL_IU94 (RD/12)CVCL_VH40 (RD/15)CVCL_IU87 (RD/18)
CVCL_VH41 (RD/19)CVCL_VH39 (RD/7)CVCL_A2HQ (RD/VCR-F3)
CVCL_1756 (TE 671)

Sex of cellFemale
Age at sampling7Y
CategoryCancer cell line
STR profileSource(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; COG; ECACC; JCRB; KCLB; PubMed=20922763; PubMed=21948088

Markers:
AmelogeninX
CSF1PO10,11
D2S133817,23
D3S135815,17
D5S81811
D7S8208,12
D8S117911,15
D13S31713
D16S53910,11
D18S5113,18
D19S43311,14
D21S1128,29
FGA20,21
Penta D11,13
Penta E12
TH019.3
TPOX9
vWA18

Run an STR similarity search on this cell line
Web pageshttp://www.cccells.org/cellreqs-ncipptp.php
http://www.pptpinvitro.org/cell_lines_panel.php
https://en.vircell.com/products/rd-cell-line/
https://tcpaportal.org/mclp/
Publications

PubMed=4241949; DOI=10.1002/1097-0142(196909)24:3<520::aid-cncr2820240313>3.0.CO;2-M
McAllister R.M., Melnyk J., Finkelstein J.Z., Adams E.C. Jr., Gardner M.B.
Cultivation in vitro of cells derived from a human rhabdomyosarcoma.
Cancer 24:520-526(1969)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x
Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.
Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique.
Tissue Antigens 11:279-286(1978)

PubMed=7309287; DOI=10.1002/ijc.2910280403
Houghton J.A., Houghton P.J., Brodeur G.M., Green A.A.
Development of resistance to vincristine in a childhood rhabdomyosarcoma growing in immune-deprived mice.
Int. J. Cancer 28:409-415(1981)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=3158613; DOI=10.1002/ijc.2910350513
Chardin P., Yeramian P., Madaule P., Tavitian A.
N-ras gene activation in the RD human rhabdomyosarcoma cell line.
Int. J. Cancer 35:647-652(1985)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2216456
Stratton M.R., Moss S., Warren W., Patterson H., Clark J., Fisher C., Fletcher C.D.M., Ball A., Thomas M., Gusterson B.A., Cooper C.S.
Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.
Oncogene 5:1297-1301(1990)

PubMed=2302710
Ozkaynak M.F., Nolta J., Parkman R.
In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide.
Cancer Res. 50:1455-1458(1990)

CLPUB00569
Dickman P.S., Tsokos M.G., Triche T.J.
Biology of rhabdomyosarcoma: cell culture, xenografts, and animal models.
(In) Rhabdomyosarcoma and related tumors in children and adolescents; Maurer H.M., Ruymann F.B., Pochedly C.E. (eds.); pp.49-88; CRC Press; Boca Raton (1991)

PubMed=1917385
Lollini P.-L., De Giovanni C., Landuzzi L., Nicoletti G., Scotlandi K., Nanni P.
Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells.
Invasion Metastasis 11:116-124(1991)

PubMed=8275086; DOI=10x.1038/ng1193-230
Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S., Rauscher F.J. III, Emanuel B.S., Rovera G., Barr F.G.
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.
Nat. Genet. 5:230-235(1993)

PubMed=8383879; DOI=10.1126/science.8383879
Tapscott S.J., Thayer M.J., Weintraub H.M.
Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis.
Science 259:1450-1453(1993)

PubMed=10899454; DOI=10.1016/s0960-8966(00)00096-1
Vergani L., Prescott A.R., Holt I.J.
Rhabdomyosarcoma rho(0) cells: isolation and characterization of a mitochondrial DNA depleted cell line with 'muscle-like' properties.
Neuromuscul. Disord. 10:454-459(2000)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=16518851; DOI=10.1002/gcc.20322
Chen Y., Takita J., Hiwatari M., Igarashi T., Hanada R., Kikuchi A., Hongo T., Taki T., Ogasawara M., Shimada A., Hayashi Y.
Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Genes Chromosomes Cancer 45:583-591(2006)

PubMed=17471488; DOI=10.1002/path.2170
Lae M., Ahn E.H., Mercado G.E., Chuai S., Edgar M., Pawel B.R., Olshen A., Barr F.G., Ladanyi M.
Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
J. Pathol. 212:143-151(2007)

PubMed=19235922; DOI=10.1002/gcc.20655
Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C., Koster J., Summersgill B.M., Messahel B., Versteeg R., Pritchard-Jones K., Kool M., Shipley J.M.
Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.
Genes Chromosomes Cancer 48:455-467(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=21948088; DOI=10.1158/1078-0432.CCR-11-1004
Belyea B.C., Naini S., Bentley R.C., Linardic C.M.
Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Clin. Cancer Res. 17:7324-7336(2011)

PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056
Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A., Borsu L., Barr F.G., Ladanyi M.
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Clin. Cancer Res. 18:748-757(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22541669; DOI=10.1186/2044-5040-2-7
Macquarrie K.L., Yao Z.-Z., Young J.M., Cao Y., Tapscott S.J.
miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells.
Skelet. Muscle 2:7.1-7.14(2012)

PubMed=23578105; DOI=10.1111/cas.12173
Nishimura R., Takita J., Sato-Otsubo A., Kato M., Koh K., Hanada R., Tanaka Y., Kato K., Maeda D., Fukayama M., Sanada M., Hayashi Y., Ogawa S.
Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
Cancer Sci. 104:856-864(2013)

PubMed=23828214; DOI=10.3892/or.2013.2588
Yamamoto Y., Fukuda K., Fuchimoto Y., Matsuzaki Y., Saikawa Y., Kitagawa Y., Morikawa Y., Kuroda T.
Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro.
Oncol. Rep. 30:1081-1086(2013)

PubMed=23882450; DOI=10.3389/fonc.2013.00183
Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G., Linardic C.M.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183.1-183.12(2013)

PubMed=25894527; DOI=10.1371/journal.pone.0121314
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31448612; DOI=10.1021/acs.jproteome.9b00157
Rammal G., Fahs A., Kobeissy F., Mechref Y., Zhao J., Zhu R., Diab-Assaf M., Saab R., Ghayad S.E.
Proteomic profiling of rhabdomyosarcoma-derived exosomes yield insights into their functional role in paracrine signaling.
J. Proteome Res. 18:3567-3579(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line databases/resourcesCLO; CLO_0008693
CLO; CLO_0008770
CLDB; cl4119
CLDB; cl4120
CLDB; cl4121
CLDB; cl4122
CLDB; cl4123
CLDB; cl4124
CLDB; cl4125
CLDB; cl4126
CLDB; cl4127
CCRID; 1101HUM-PUMC000293
CCRID; 1102HUM-NIFDC00079
CCRID; 3101HUMTCHu45
CCRID; 4201HUM-CCTCC00295
Cell_Model_Passport; SIDM00847
Cosmic-CLP; 909264
DepMap; ACH-000169
IGRhCellID; RD
LINCS_LDP; LCL-1411
Lonza; 1536
TOKU-E; 2986
Anatomy/cell type resourcesBTO; BTO:0005377
Biological sample resourcesBioSample; SAMN01821591
BioSample; SAMN01821716
BioSample; SAMN03472710
BioSample; SAMN10988441
Cell line collections (Providers)AddexBio; C0035001/4950
ATCC; CCL-136
ATCC; CRL-7713 - Discontinued
ATCC; CRL-7731 - Discontinued
ATCC; HTB-97 - Discontinued
BCRC; 60113
BCRJ; 0260
CCTCC; GDC0295
CLS; 300401
ECACC; 85111502
IZSLER; BS TCL 57
JCRB; JCRB9072
KCLB; 10136
Chemistry resourcesChEMBL-Cells; CHEMBL3307547
ChEMBL-Targets; CHEMBL614144
GDSC; 909264
PharmacoDB; RD_1296_2019
PubChem_Cell_line; CVCL_1649
Encyclopedic resourcesWikidata; Q54949532
Experimental variables resourcesEFO; EFO_0002315

更多>>相关产品

总部地址:北京市怀柔区渤海镇怀沙路536号

关注我们
在线咨询
在线客服
电话咨询
微信客服
返回顶部